In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Concert Pharmaceuticals, Inc.. Trade Record

NASDAQ:CNCE Concert Pharmaceuticals, Inc. stock gains 7.03% Exit Jan 9, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CNCE Dec 22, 2016, priceSeries
About Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.74
Entry Date
Dec 22, 2016
Entry Price
9.54
Sell Date
Jan 9, 2017
Sell Price
10.21
Net Gain
7.03%
Hold Time
10 Trading Days